Create a Free Account
or
Create a Free Account
or
| # | Filing Date | Period End Date | Type | Report Link |
|---|---|---|---|---|
| No Data found | ||||
| # | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
|---|
Maxim Group analyst Naz Rahman maintains Aytu BioPharma (NASDAQ: AYTU) with a Buy and lowers the price target from $9 to $7.
Ascendiant Capital analyst Edward Woo maintains Aytu BioPharma (NASDAQ: AYTU) with a Buy and raises the price target from $1...
Aytu BioPharma (NASDAQ:AYTU) reported quarterly losses of $(2.92) per share which missed the analyst consensus estimate of $(0....
https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/aytu-biopharma-716599-09092025
